01/25/2024
🛎️ 🎉 Big congratulations to our client, CG Oncology!
IRVINE, Calif.--(BUSINESS WIRE)--CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the pricing of its upsized initial public offering of 20,000,000 shares of its common stock at an initial public offering price of $19.00 per share.
Read more: https://bwnews.pr/499xRxm